Biotage is strongly committed to SwedenBIO and the industry, why are you doing this?
“For us, it is a matter of course to be involved in influencing and driving development forward. SwedenBIO does an important job in this context and we want to contribute as much as we can. Sweden has a rich history of successful companies in the industry, and we see it as very important to try to ensure this also in the future by influencing and participating in the public debate and putting more successful Swedish companies on the world map.”
What impact do you want to make as a board member of SwedenBIO?
“I hope that, together with my board colleagues, I can provide SwedenBIO’s operational management with valuable support in their work. I see it as particularly important to be involved in influencing the funding of early research and early start-ups. Here I believe it is very important that society provides the right conditions for us to have a steady supply of successful companies and also medium-sized companies in our industry. This ensures continued growth and success for Sweden as an innovative nation.”
What industry trends do you see and what is happening at Biotage this fall?
“It’s full speed ahead and very positive at Biotage. Of course, like everyone else, we hope that easing restrictions in society will allow us to get out and meet our customers in real life. Our talented staff have managed a long period without physical meetings, but this is also something we are now planning to make up for. I think Biotage is in a good position at the moment, where we have clarified our identity and direction, allocated our resources very sensibly, and managed to strengthen our finances. We have weathered a tough time very successfully with three record quarters in a row and we feel equipped to take on new challenges. In particular, we hope to continue contributing to the delivery of solutions for our customers that contribute to the benefit of society and make the world more sustainable, healthy and cleaner. We are particularly proud of our work with vaccine manufacturers and developers. It feels good to contribute to this important work and of course we want to continue it.”
